Photo from wikipedia
Key Points • In the PHOENIX trial, the addition of ibrutinib to R-CHOP did not improve the survival of patients with previously untreated non-GCB DLBCL.• This study identified a patient… Click to show full abstract
Key Points • In the PHOENIX trial, the addition of ibrutinib to R-CHOP did not improve the survival of patients with previously untreated non-GCB DLBCL.• This study identified a patient subset with high BCL2/MYC coexpression using RNA sequencing, with improved EFS after R-CHOP with ibrutinib.
Keywords:
chop;
dlbcl;
bcl2 myc;
clinical impact;
phoenix trial
Journal Title: Blood Advances
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!